Invited discussant

Date

20 Dec 2015

Session

Presidential Symposium

Presenters

Tony S.K. Mok

Authors

T.S.K. Mok

Author affiliations

Department Of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong/CN

Resources

Watch the webcast View the presentation

View the abstracts discussed:

KEYNOTE-010: Phase 2/3 study of pembrolizumab (MK-3475) vs docetaxel for PD-L1-positive NSCLC after platinum-based therapy

Resources from the same session

20 Dec 2015

Prioritizing strategies to address the economic impact of cancer in Southeast Asia

Presenter: Nirmala Bhoo-Pathy

Session: Presidential Symposium

Resources:

Abstract

20 Dec 2015

KEYNOTE-010: Phase 2/3 study of pembrolizumab (MK-3475) vs docetaxel for PD-L1–positive NSCLC after platinum-based therapy

Presenter: Roy S. Herbst

Session: Presidential Symposium

Resources:

Abstract

Presentation

Webcast

20 Dec 2015

Invited discussant

Presenter: Roman Rouzier

Session: Presidential Symposium

Resources:

Presentation

Webcast

20 Dec 2015

Invited discussant

Presenter: Pasi Jänne

Session: Presidential Symposium

Resources:

Presentation

Webcast

20 Dec 2015

Afatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7 (LL7)

Presenter: Keunchil Park

Session: Presidential Symposium

Resources:

Abstract

Presentation

Webcast